Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood blood.2024025454.

https://doi.org/10.1182/blood.2024025454

Published: 2024

Includes: Supplemental data

Journal Articles

Orthotopic Heart Transplantation Followed By Autologous Stem Cell Transplantation in Patients with Cardiac AL Amyloidosis: Results from a Single Centre Prospective Study

Harshita Rajasekariah, Georgia McCaughan, Chun Kei Kris Ma, Natasha Gorrie, Samuel Milliken, David Ma, Keith Fay, Barbara Withers, Nada Hamad, Samuel Birch, Anne Keogh, Andrew Jabbour, Christopher Hayward, Peter Macdonald, John Moore

Blood (2023) 142 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2023-184319

Published: 2023

Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster

Blood (2023) 142 (Supplement 1): 1752.

https://doi.org/10.1182/blood-2023-190201

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 603.

https://doi.org/10.1182/blood-2023-173692

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde

Blood (2022) 140 (Supplement 1): 1467–1470.

https://doi.org/10.1182/blood-2022-157691

Published: 2022

Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Blood (2022) 140 (Supplement 1): 3753–3755.

https://doi.org/10.1182/blood-2022-157729

Published: 2022

Journal Articles

Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index

Jacinta Perram, Eleni Mayson, Catherine Tang, Steven Tran, Donna Aarons, Anthony J Dodds, Keith Fay, Nada Hamad, David Ma, Sam Milliken, Barbara Withers, Matthew Greenwood, William S Stevenson, Christopher Kevin Arthur, Ian H Kerridge, John Moore

Blood (2021) 138 (Supplement 1): 3958.

https://doi.org/10.1182/blood-2021-147106

Published: 2021

Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2021-147937

Published: 2021

Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 127.

https://doi.org/10.1182/blood-2021-145872

Published: 2021

Journal Articles

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Prue Hardefeldt, MBBS, John Moore, MDFRACP,FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Keith Fay, FRCP,FRCPath,MB, Lavee Orly, MBBS, Eleni Mayson, FRACP, FRCPA, MBBS, MPhil, Barbara Withers, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2019) 134 (Supplement_1): 5336.

https://doi.org/10.1182/blood-2019-125154

Published: 2019

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study

Louise Imlay-Gillespie, BMed, Caroline Dix, MBBS, Ashley McEwan, MD, Kelly Wong, Melanie Figtree, MBBS, Christopher Arthur, MD, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William Stevenson, MBBS, PhD, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA

Blood (2015) 126 (23): 2108.

https://doi.org/10.1182/blood.V126.23.2108.2108

Published: 2015

Journal Articles

Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders

Louise Imlay-Gillespie, BMed, David Simon Kliman, MBBS, Kelly Wong, Christopher Arthur, MD, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB FRACP FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William Stevenson, MBBS, PhD, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 5038.

https://doi.org/10.1182/blood.V126.23.5038.5038

Published: 2015

Journal Articles

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

David Simon Kliman, MBBS, Louise Imlay-Gillespie, BMed, Kirsten McIlroy, MBBS, FRCPA, Anthony Gill, MBBS, MD FRCPA, Christopher Arthur, MBBS, FRACP, FRCPA, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB, FRACP, FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William S Stevenson, MBBS, PhD FRACP, FRCPA, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 2656.

https://doi.org/10.1182/blood.V126.23.2656.2656

Published: 2015

Journal Articles

Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients

Christopher Arthur, Charmaine Wong, MB BS, Brandon Aubrey, MB BS, Eunice Liu, MB BS, William Stevenson, MBBS, PhD, Gary Soo, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB, Matthew Greenwood, MD, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Christopher M Ward, MB, PhD

Blood (2012) 120 (21): 3612.

https://doi.org/10.1182/blood.V120.21.3612.3612

Published: 2012

Journal Articles

High Response Rate in Patients with De-Novo or Relapsed/Refractory Acute Myeloid Leukemia Using a Novel Strategy of Low-Dose, Prolonged Administration of Cytarabine and Thioguanine in Combination with Filgrastim in the Ambulatory Setting: A Single-Center, Retrospective Study

Christopher K Arthur, MBBS, FRACP, FRCPA, Brandon Aubrey, MB BS, Matthew Greenwood, MD, FRCPA, FRACP, Keith Fay, MBChB, Luke Coyle, MBBS, FRACP, FRCPA, Eunice Liu, MB BS, Christopher Ward, MB, CHB, PhD, Garry Soo, Naomi Mackinlay, MB BS FRACP FRCPA, William s Stevenson, MBBS, PhD

Blood (2011) 118 (21): 2624.

https://doi.org/10.1182/blood.V118.21.2624.2624

Published: 2011

Journal Articles

A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,

Adam J Bryant, Elango Pillai, Glen Kennedy, Anna Kalff, David Ritchie, Biju George, Mark Hertzberg, Sushrut S. Patil, FRACP FRCPA, Andrew Spencer, MD, Keith Fay, Paul Cannell, Leanne Berkahn, Richard Doocey, Ruth Spearling, Ian Nivison-Smith, John Moore

Blood (2011) 118 (21): 4143.

https://doi.org/10.1182/blood.V118.21.4143.4143

Published: 2011

Journal Articles

Sustained Complete Metabolic Remission After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE).

Joerg Halter, WM Michael Schuepbach, Carlo Casali, Ronit Elhasid, Keith Fay, Simon Hammans, Isabel Illa, Liliane Kappeler, Stephan Kraehenbuehl, Thomas Lehmann, Hanna Mandel, Ramon Marti, Heinrich Mattle, Kim H. Orchard, David Savage, Carolyn Sue, David Valcárcel, Alois Gratwohl, Michio Hirano

Blood (2009) 114 (22): 1181.

https://doi.org/10.1182/blood.V114.22.1181.1181

Published: 2009

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

NARROW

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Orthotopic Heart Transplantation Followed By Autologous Stem Cell Transplantation in Patients with Cardiac AL Amyloidosis: Results from a Single Centre Prospective Study

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study

Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients

High Response Rate in Patients with De-Novo or Relapsed/Refractory Acute Myeloid Leukemia Using a Novel Strategy of Low-Dose, Prolonged Administration of Cytarabine and Thioguanine in Combination with Filgrastim in the Ambulatory Setting: A Single-Center, Retrospective Study

A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,

Sustained Complete Metabolic Remission After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE).

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only